Oramed Reports Fiscal Third Quarter 2025 Financial Results

Core Insights - Oramed Pharmaceuticals Inc. reported a strong financial performance for the nine months ended September 30, 2025, with total assets increasing by 42% to $220.5 million [1][7] - The company achieved a net income of $65 million, a significant turnaround from a net loss of $6.1 million in the same period last year, primarily due to cash returns from Scilex Holding Company and unrealized gains from investments in Alpha Tau Medical Ltd. [3][4][7] Financial Highlights - Net income (pre-tax) reached $65.0 million, compared to a net loss of $6.1 million in the same period last year [7] - The company completed a full repayment from Scilex, receiving approximately $27 million during the period, totaling $100 million in principal return from this strategic investment [4][7] - Basic earnings per share were reported at $1.30, while diluted earnings per share were $1.26 [7] - Total assets grew from $155.3 million to $220.5 million year-over-year, marking a 42% increase [7] - Research and Development (R&D) expenses decreased from $4.9 million to $4.4 million, while General and Administrative (G&A) expenses increased from $4.3 million to $5.0 million [7] Management Commentary - CEO Nadav Kidron emphasized that the disciplined investment strategy is yielding strong results, providing the company with greater financial flexibility to pursue strategic opportunities while advancing its oral drug delivery platform [4]